select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Anxiety Disorders-Pipeline Review, H2 2016

Anxiety Disorders-Pipeline Review, H2 2016


  • Products Id :- GMDHC8433IDB
  • |
  • Pages: 273
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Anxiety Disorders-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Anxiety Disorders-Pipeline Review, H2 2016', provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders

The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects

The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Anxiety Disorders Overview 11

Therapeutics Development 12

Pipeline Products for Anxiety Disorders-Overview 12

Pipeline Products for Anxiety Disorders-Comparative Analysis 13

Anxiety Disorders-Therapeutics under Development by Companies 14

Anxiety Disorders-Therapeutics under Investigation by Universities/Institutes 18

Anxiety Disorders-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Anxiety Disorders-Products under Development by Companies 23

Anxiety Disorders-Products under Investigation by Universities/Institutes 29

Anxiety Disorders-Companies Involved in Therapeutics Development 30

AbbVie Inc 30

Ache Laboratorios Farmaceuticos S/A 31

Adamed Sp. z o.o. 32

Addex Therapeutics Ltd 33

Amorsa Therapeutics Inc. 34

Avineuro Pharmaceuticals, Inc. 35

Azevan Pharmaceuticals, Inc. 36

Biohaven Pharmaceutical Holding Company Limited 37

Bionomics Limited 38

Boehringer Ingelheim GmbH 39

C4X Discovery Holdings PLC 40

Catalyst Pharmaceuticals, Inc. 41

Corcept Therapeutics Incorporated 42

Edgemont Pharmaceuticals, LLC 43

Eisai Co., Ltd. 44

Eli Lilly and Company 45

Fabre-Kramer Pharmaceuticals, Inc. 46

Gabather AB 47

GlaxoSmithKline Plc 48

GW Pharmaceuticals Plc 49

Humanetics Corporation 50

IntelGenx Corp. 51

Intra-Cellular Therapies, Inc. 52

INVENT Pharmaceuticals, Inc. 53

Lead Discovery Center GmbH 54

Marinus Pharmaceuticals, Inc. 55

Merz Pharma GmbH & Co. KgaA 56

Neuralstem, Inc. 57

Neurelis, Inc. 58

NeuroNascent, Inc. 59

Newron Pharmaceuticals S.p.A. 60

Nippon Chemiphar Co., Ltd. 61

Omeros Corporation 62

Otsuka Holdings Co., Ltd. 63

Pherin Pharmaceuticals, Inc. 64

Pragma Therapeutics 65

Protagenic Therapeutics Inc. 66

Suda Ltd 67

Sumitomo Dainippon Pharma Co., Ltd. 68

Synchroneuron Inc. 69

Tonix Pharmaceuticals Holding Corp. 70

Toray Industries, Inc. 71

Trevena, Inc. 72

TRImaran Pharma, Inc. 73

Turing Pharmaceuticals AG 74

Anxiety Disorders-Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Target 76

Assessment by Mechanism of Action 81

Assessment by Route of Administration 85

Assessment by Molecule Type 87

Drug Profiles 89

18-MC-Drug Profile 89

acamprosate calcium SR-Drug Profile 90

ACH-36-Drug Profile 92

ADN-2013-Drug Profile 93

ADX-71441-Drug Profile 94

ADX-71743-Drug Profile 98

ADX-88178-Drug Profile 99

alprazolam-Drug Profile 101

AM-3506-Drug Profile 102

AVN-0189-Drug Profile 103

AVN-101-Drug Profile 104

AVN-628-Drug Profile 105

BNC-210-Drug Profile 106

brexpiprazole-Drug Profile 109

CPP-115-Drug Profile 115

D-473-Drug Profile 119

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders-Drug Profile 120

E-2508-Drug Profile 121

evenamide-Drug Profile 122

FKW-00GA-Drug Profile 125

fluvoxamine maleate-Drug Profile 126

ganaxolone-Drug Profile 127

gepirone hydrochloride ER-Drug Profile 132

GT-001-Drug Profile 134

HL-9001-Drug Profile 135

HUF-101-Drug Profile 136

IC-87201-Drug Profile 137

INT-0036-Drug Profile 138

INV-107-Drug Profile 139

ITI-007-Drug Profile 140

KDAC-0001-Drug Profile 148

ketamine hydrochloride-Drug Profile 149

lorazepam-Drug Profile 150

lorazepam ER-Drug Profile 151

LSN-2535717-Drug Profile 152

LY-2607540-Drug Profile 153

midazolam hydrochloride-Drug Profile 154

modafinil-Drug Profile 155

nabiximols-Drug Profile 156

NC-2800-Drug Profile 163

NEO-1940-Drug Profile 164

NNI-351-Drug Profile 165

NSI-189-Drug Profile 166

OMS-527-Drug Profile 170

Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders-Drug Profile 172

PGT-117-Drug Profile 173

PH-94B-Drug Profile 174

PN-6047-Drug Profile 176

PT-00114-Drug Profile 177

remeglurant-Drug Profile 178

riluzole-Drug Profile 179

Rycal-Drug Profile 182

S-107-Drug Profile 183

SCT-66-Drug Profile 184

Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders-Drug Profile 185

Small Molecule to Agonize CB1 Receptor for Inflammatory and Neuropathic Pain-Drug Profile 186

Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders-Drug Profile 187

Small Molecule to Antagonize GPR31 for Anxiety Disorders-Drug Profile 188

Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder-Drug Profile 189

Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis-Drug Profile 190

Small Molecule to Target GPR83 for CNS and Immunological Disorders-Drug Profile 191

Small Molecule to Target Oxytocin for Autism and Anxiety Disorders-Drug Profile 192

Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders-Drug Profile 193

Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders-Drug Profile 194

Small Molecules to Activate Translocator Protein for Anxiety-Drug Profile 195

Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders-Drug Profile 196

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety-Drug Profile 197

Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder-Drug Profile 198

Small Molecules to Antagonize mGlu2 for Anxiety and Depression-Drug Profile 199

Small Molecules to Antagonize mGluR3 for Anxiety and Depression-Drug Profile 200

Small Molecules to Antagonize mGluR5 for Anxiety-Drug Profile 201

Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders-Drug Profile 202

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders-Drug Profile 203

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 204

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy-Drug Profile 205

Small Molecules to Modulate Mineralocorticoid Receptor for Anxiety Disorders and Depression-Drug Profile 206

Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder-Drug Profile 207

Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder-Drug Profile 208

Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder-Drug Profile 209

SRX-246-Drug Profile 210

SRX-251-Drug Profile 212

STX-Drug Profile 214

Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder-Drug Profile 215

TGFK-08AA-Drug Profile 216

TGSC-01AA(4)-Drug Profile 217

TNX-102-Drug Profile 218

TRV-250-Drug Profile 227

UCM-765-Drug Profile 228

Vaccine for CNS Disorders-Drug Profile 229

VAD-1-Drug Profile 230

VAD-2-Drug Profile 231

VU-0431316-Drug Profile 232

VU-0456810-Drug Profile 233

ZL-006-Drug Profile 234

Anxiety Disorders-Dormant Projects 235

Anxiety Disorders-Discontinued Products 250

Anxiety Disorders-Product Development Milestones 255

Featured News & Press Releases 255

Appendix 266

Methodology 266

Coverage 266

Secondary Research 266

Primary Research 266

Expert Panel Validation 266

Contact Us 266

Disclaimer 267

List of Figures

Number of Products under Development for Anxiety Disorders, H2 2016 18

Number of Products under Development for Anxiety Disorders-Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Products, H2 2016 27

Assessment by Monotherapy Products, H2 2016 81

Number of Products by Top 10 Targets, H2 2016 82

Number of Products by Stage and Top 10 Targets, H2 2016 82

Number of Products by Top 10 Mechanism of Actions, H2 2016 87

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 87

Number of Products by Routes of Administration, H2 2016 91

Number of Products by Stage and Routes of Administration, H2 2016 91

Number of Products by Molecule Types, H2 2016 93

Number of Products by Stage and Molecule Types, H2 2016 93

List of Tables

Number of Products under Development for Anxiety Disorders, H2 2016 18

Number of Products under Development for Anxiety Disorders-Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Development by Companies, H2 2016 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Development, H2 2016 27

Comparative Analysis by Unknown Stage Development, H2 2016 28

Products under Development by Companies, H2 2016 29

Products under Development by Companies, H2 2016 (Contd..1) 30

Products under Development by Companies, H2 2016 (Contd..2) 31

Products under Development by Companies, H2 2016 (Contd..3) 32

Products under Development by Companies, H2 2016 (Contd..4) 33

Products under Development by Companies, H2 2016 (Contd..5) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Anxiety Disorders-Pipeline by AbbVie Inc, H2 2016 36

Anxiety Disorders-Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 37

Anxiety Disorders-Pipeline by Adamed Sp. z o.o., H2 2016 38

Anxiety Disorders-Pipeline by Addex Therapeutics Ltd, H2 2016 39

Anxiety Disorders-Pipeline by Amorsa Therapeutics Inc., H2 2016 40

Anxiety Disorders-Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016 41

Anxiety Disorders-Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 42

Anxiety Disorders-Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 43

Anxiety Disorders-Pipeline by Bionomics Limited, H2 2016 44

Anxiety Disorders-Pipeline by Boehringer Ingelheim GmbH, H2 2016 45

Anxiety Disorders-Pipeline by C4X Discovery Holdings PLC, H2 2016 46

Anxiety Disorders-Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 47

Anxiety Disorders-Pipeline by Corcept Therapeutics Incorporated, H2 2016 48

Anxiety Disorders-Pipeline by Edgemont Pharmaceuticals, LLC, H2 2016 49

Anxiety Disorders-Pipeline by Eisai Co., Ltd., H2 2016 50

Anxiety Disorders-Pipeline by Eli Lilly and Company, H2 2016 51

Anxiety Disorders-Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 52

Anxiety Disorders-Pipeline by Gabather AB, H2 2016 53

Anxiety Disorders-Pipeline by GlaxoSmithKline Plc, H2 2016 54

Anxiety Disorders-Pipeline by GW Pharmaceuticals Plc, H2 2016 55

Anxiety Disorders-Pipeline by Humanetics Corporation, H2 2016 56

Anxiety Disorders-Pipeline by IntelGenx Corp., H2 2016 57

Anxiety Disorders-Pipeline by Intra-Cellular Therapies, Inc., H2 2016 58

Anxiety Disorders-Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 59

Anxiety Disorders-Pipeline by Lead Discovery Center GmbH, H2 2016 60

Anxiety Disorders-Pipeline by Marinus Pharmaceuticals, Inc., H2 2016 61

Anxiety Disorders-Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 62

Anxiety Disorders-Pipeline by Neuralstem, Inc., H2 2016 63

Anxiety Disorders-Pipeline by Neurelis, Inc., H2 2016 64

Anxiety Disorders-Pipeline by NeuroNascent, Inc., H2 2016 65

Anxiety Disorders-Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 66

Anxiety Disorders-Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 67

Anxiety Disorders-Pipeline by Omeros Corporation, H2 2016 68

Anxiety Disorders-Pipeline by Otsuka Holdings Co., Ltd., H2 2016 69

Anxiety Disorders-Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 70

Anxiety Disorders-Pipeline by Pragma Therapeutics, H2 2016 71

Anxiety Disorders-Pipeline by Protagenic Therapeutics Inc., H2 2016 72

Anxiety Disorders-Pipeline by Suda Ltd, H2 2016 73

Anxiety Disorders-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 74

Anxiety Disorders-Pipeline by Synchroneuron Inc., H2 2016 75

Anxiety Disorders-Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 76

Anxiety Disorders-Pipeline by Toray Industries, Inc., H2 2016 77

Anxiety Disorders-Pipeline by Trevena, Inc., H2 2016 78

Anxiety Disorders-Pipeline by TRImaran Pharma, Inc., H2 2016 79

Anxiety Disorders-Pipeline by Turing Pharmaceuticals AG , H2 2016 80

Assessment by Monotherapy Products, H2 2016 81

Number of Products by Stage and Target, H2 2016 83

Number of Products by Stage and Mechanism of Action, H2 2016 88

Number of Products by Stage and Route of Administration, H2 2016 92

Number of Products by Stage and Molecule Type, H2 2016 94

Anxiety Disorders-Dormant Projects, H2 2016 241

Anxiety Disorders-Dormant Projects (Contd..1), H2 2016 242

Anxiety Disorders-Dormant Projects (Contd..2), H2 2016 243

Anxiety Disorders-Dormant Projects (Contd..3), H2 2016 244

Anxiety Disorders-Dormant Projects (Contd..4), H2 2016 245

Anxiety Disorders-Dormant Projects (Contd..5), H2 2016 246

Anxiety Disorders-Dormant Projects (Contd..6), H2 2016 247

Anxiety Disorders-Dormant Projects (Contd..7), H2 2016 248

Anxiety Disorders-Dormant Projects (Contd..8), H2 2016 249

Anxiety Disorders-Dormant Projects (Contd..9), H2 2016 250

Anxiety Disorders-Dormant Projects (Contd..10), H2 2016 251

Anxiety Disorders-Dormant Projects (Contd..11), H2 2016 252

Anxiety Disorders-Dormant Projects (Contd..12), H2 2016 253

Anxiety Disorders-Dormant Projects (Contd..13), H2 2016 254

Anxiety Disorders-Dormant Projects (Contd..14), H2 2016 255

Anxiety Disorders-Discontinued Products, H2 2016 256

Anxiety Disorders-Discontinued Products (Contd..1), H2 2016 257

Anxiety Disorders-Discontinued Products (Contd..2), H2 2016 258

Anxiety Disorders-Discontinued Products (Contd..3), H2 2016 259

Anxiety Disorders-Discontinued Products (Contd..4), H2 2016 260

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc

Ache Laboratorios Farmaceuticos S/A

Adamed Sp. z o.o.

Addex Therapeutics Ltd

Amorsa Therapeutics Inc.

Avineuro Pharmaceuticals, Inc.

Azevan Pharmaceuticals, Inc.

Biohaven Pharmaceutical Holding Company Limited

Bionomics Limited

Boehringer Ingelheim GmbH

C4X Discovery Holdings PLC

Catalyst Pharmaceuticals, Inc.

Corcept Therapeutics Incorporated

Edgemont Pharmaceuticals, LLC

Eisai Co., Ltd.

Eli Lilly and Company

Fabre-Kramer Pharmaceuticals, Inc.

Gabather AB

GlaxoSmithKline Plc

GW Pharmaceuticals Plc

Humanetics Corporation

IntelGenx Corp.

Intra-Cellular Therapies, Inc.

INVENT Pharmaceuticals, Inc.

Lead Discovery Center GmbH

Marinus Pharmaceuticals, Inc.

Merz Pharma GmbH & Co. KgaA

Neuralstem, Inc.

Neurelis, Inc.

NeuroNascent, Inc.

Newron Pharmaceuticals S.p.A.

Nippon Chemiphar Co., Ltd.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pherin Pharmaceuticals, Inc.

Pragma Therapeutics

Protagenic Therapeutics Inc.

Suda Ltd

Sumitomo Dainippon Pharma Co., Ltd.

Synchroneuron Inc.

Tonix Pharmaceuticals Holding Corp.

Toray Industries, Inc.

Trevena, Inc.

TRImaran Pharma, Inc.

Turing Pharmaceuticals AG

Anxiety Disorders Therapeutic Products under Development, Key Players in Anxiety Disorders Therapeutics, Anxiety Disorders Pipeline Overview, Anxiety Disorders Pipeline, Anxiety Disorders Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com